Proteomic study of breast cancer cell line after hemeoxygenase-1 modulation by hemin treatment

SCHWEITZER K; FERNANDEZ CHAVEZ L; ALONSO EG; MASCARO M; ORESTI GM; BORISOV A; FACCHINETTI MM; CURINO AC; FASSLER R; COLO GP; GANDINI NA

Congreso; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); 2019

LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC)

Hemoxygenase-1 (HO-1) is a microsomal enzymethat catalyzes the degradation of the heme group and it can be translocated tomultiple subcellular compartments. Our laboratory, among others, has shown thatHO-1 regulates several processes related to cancer progression such as:proliferation, invasion migration, metastasis and the epithelial-mesenchymaltransition. The aim of this work is to investigate the role of HO-1 in the proteomemodulation in a breast cancer cell line. Protein extracts of LM3 cell linetreated with hemin, a pharmacological HO-1 inducer (80µM, 24h), were obtainedand studied by Western blot and Mass Spectrometry (MS). MS-data analysis showed1033 from 7292 proteins were modulated after hemin treatment (ANOVA p